Estimaciones de analistas de Wall Street para Autolus Therapeutics plc (AUTL): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 11 |
| Mantener | 3 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 14 |
| Calificación media (1-5) | 0.79 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.20 | ||
| 2026-08-11 | $-0.15 | $-0.21 | +28.6% |
| 2026-05-14 | $-0.27 | $-0.29 | +6.9% |
| 2026-03-27 | $-0.34 | $-0.26 | -30.8% |
| 2025-11-12 | $-0.30 | $-0.23 | -30.4% |
| 2025-08-12 | $-0.18 | $-0.24 | +25.0% |
| 2025-05-08 | $-0.26 | $-0.24 | -8.3% |
| 2025-03-20 | $-0.09 | $-0.21 | +57.1% |
Ratios de valoración
| Precio / Valor contable | 6.51 |
| EV / EBITDA | -2.30 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $1.2M | $1.7M | $1.0M | $2.9M | $1.7M | $1.5M | $6.2M | $1.7M | $10.1M | $75.6M |
| Coste de Ventas | $478000 | $1.0M | $48.3M | $105.4M | $134.9M | 0 | 0 | 0 | $141.0M | $96.6M |
| Beneficio Bruto | $734000 | $684000 | -$47.3M | -$102.5M | -$133.2M | $1.5M | $6.2M | $1.7M | -$130.9M | -$21.0M |
| I+D | $10.4M | $16.0M | $24.6M | $105.6M | $135.0M | $110.8M | $117.4M | $130.5M | $158.1M | $128.6M |
| Generales y Administrativos | $5.2M | $9.1M | $16.8M | $39.5M | $35.0M | $31.9M | $31.9M | $46.7M | 0 | $131.8M |
| Gastos Operativos | $15.6M | $25.1M | $41.5M | $145.1M | $170.0M | $141.9M | $149.1M | $181.4M | $110.5M | $260.4M |
| Beneficio Operativo | -$14.4M | -$23.4M | -$57.5M | -$247.6M | -$303.1M | -$140.4M | -$142.9M | -$179.7M | -$241.4M | -$281.4M |
| EBITDA | -$13.9M | -$22.4M | -$50.3M | -$137.4M | -$162.6M | -$132.5M | -$132.2M | -$156.8M | -$233.1M | -$250.3M |
| Gastos por Intereses | 0 | 0 | $12667 | 0 | 0 | $1.1M | $8.9M | $45.1M | $9.3M | $36.8M |
| Beneficio Antes de Impuestos | -$14.3M | -$23.4M | -$36.3M | -$108.7M | -$166.3M | -$142.0M | -$148.6M | -$208.4M | -$219.1M | -$296.8M |
| Impuestos | -$1.8M | -$3.7M | -$5.2M | $15.2M | -$24.2M | $58000 | $272000 | -$19000 | $1.5M | -$8.6M |
| Beneficio Neto | -$12.6M | -$19.7M | -$31.1M | -$123.8M | -$142.1M | -$142.1M | -$148.8M | -$208.4M | -$220.7M | -$288.2M |
| BPA | $-0.91 | $-1.43 | $-0.99 | $-2.88 | $-2.76 | $-1.97 | $-1.57 | $-1.20 | $-0.87 | $-1.08 |
| BPA Diluido | $-0.91 | $-1.43 | $-0.99 | $-2.88 | $-2.76 | $-1.97 | $-1.57 | $-1.20 | $-0.87 | $-1.08 |
| Acciones en Circulación (Diluidas) | $13.8M | $13.8M | $31.6M | $43.1M | $51.6M | $72.1M | $95.0M | $173.9M | $255.2M | $266.1M |
Precio
| Precio | $1.87 |
| Capitalización | $498M |
| Bolsa | NASDAQ |
| País | GB |
Empresas relacionadas: ADCT · ANNX · AURA · BNTC · LBRX · NMRA · QSI
Explorar sector: Healthcare · Biotechnology
Más secciones de AUTL: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones